Celcuity LLC - Asset Resilience Ratio
Celcuity LLC (CELC) has an Asset Resilience Ratio of 79.98% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Celcuity LLC's Asset Resilience Ratio has changed over time. Check CELC strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Celcuity LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CELC stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $380.73 Million | 79.98% |
| Total Liquid Assets | $380.73 Million | 79.98% |
Asset Resilience Insights
- Very High Liquidity: Celcuity LLC maintains exceptional liquid asset reserves at 79.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Celcuity LLC Industry Peers by Asset Resilience Ratio
Compare Celcuity LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
INVENTIVA ADS/1 O.N.
F:6IVA |
Biotechnology | 52.73% |
|
CorMedix Inc
NASDAQ:CRMD |
Biotechnology | 0.45% |
Annual Asset Resilience Ratio for Celcuity LLC (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Celcuity LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 86.73% | $212.59 Million | $245.12 Million | +8.33pp |
| 2023-12-31 | 78.40% | $149.92 Million | $191.22 Million | -3.57pp |
| 2022-12-31 | 81.97% | $144.02 Million | $175.70 Million | +81.97pp |
| 2021-12-31 | 0.00% | $22.01 | $85.91 Million | -0.17pp |
| 2020-12-31 | 0.17% | $22.01K | $12.96 Million | +0.06pp |
| 2019-12-31 | 0.11% | $22.01K | $20.28 Million | -34.28pp |
| 2018-12-31 | 34.39% | $8.95 Million | $26.03 Million | -33.04pp |
| 2017-12-31 | 67.43% | $21.56 Million | $31.97 Million | +67.34pp |
| 2016-12-31 | 0.09% | $5.72K | $6.06 Million | -0.85pp |
| 2015-12-31 | 0.94% | $50.00K | $5.30 Million | -- |
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more